Hans M G Princen

List of Publications by Year
in descending order

114 papers	5,519 citations	87888 38 h-index	85541 71 g-index
119 all docs	119 docs citations	119 times ranked	7054 citing authors

#	Article	IF	Citations
1	No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice. Behavioural Brain Research, 2021, 396, 112875.	2.2	3
2	Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. Scientific Reports, 2021, 11, 5050.	3.3	10
3	Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?. Critical Reviews in Toxicology, 2021, 51, 141-164.	3.9	78
4	Common Variants Associated With OSMR Expression Contribute to Carotid Plaque Vulnerability, but Not to Cardiovascular Disease in Humans. Frontiers in Cardiovascular Medicine, 2021, 8, 658915.	2.4	3
5	Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. European Journal of Pharmaceutical Sciences, 2021, 161, 105776.	4.0	7
6	Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers. Frontiers in Pharmacology, 2021, 12, 681455.	3.5	2
7	Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice. Osteoarthritis and Cartilage, 2021, 29, 1314-1323.	1.3	6
8	Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. Journal of Lipid Research, 2020, 61, 365-375.	4.2	48
9	In Vivo Magnetic Resonance Imagingâ€Based Detection of Heterogeneous Endothelial Response in Thoracic and Abdominal Aorta to Shortâ€Term Highâ€Fat Diet Ascribed to Differences in Perivascular Adipose Tissue in Mice. Journal of the American Heart Association, 2020, 9, e016929.	3.7	24
10	Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice. Stroke, 2020, 51, e297-e298.	2.0	2
11	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International, 2020, 40, 2860-2876.	3.9	12
12	Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering. Basic Research in Cardiology, 2020, 115, 78.	5.9	37
13	Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. Hepatology Communications, 2020, 4, 193-207.	4.3	15
14	Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. Scientific Reports, 2019, 9, 11079.	3.3	29
15	Triple Treatment With Alirocumab And Evinacumab On Top Of Atorvastatin Regresses Lesion Size And Improves Plaque Phenotype In Apoe*3leiden.Cetp Mice. Atherosclerosis, 2019, 287, e12.	0.8	1
16	Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans. PLoS ONE, 2019, 14, e0221477.	2.5	10
17	The Structurally Engineered Fatty Acid Icosabutate Improves Lipid Metabolism And Reduces Severity Of Atherogenesis In Mice. Atherosclerosis, 2019, 287, e55.	0.8	0
18	Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice. Toxicological Sciences, 2019, 168, 519-534.	3.1	20

#	Article	IF	Citations
19	The APOE<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:msup><mml:mrow /><mml:mrow><mml:mo>â^—</mml:mo></mml:mrow></mml:msup></mml:math>3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis. Journal of Diabetes Research, 2019, 2019, 1-13.	2.3	8
20	FRI0528â€...HIGH INTENSIVE THERAPEUTIC LOWERING OF SYSTEMIC CHOLESTEROL DOES NOT AMELIORATE OA DEVELOPMENT IN KNEE JOINTS OF HUMANIZED DYSLIPIDEMIC MICE. , 2019, , .		1
21	Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings. Amino Acids, 2018, 50, 799-821.	2.7	23
22	Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought. Osteoarthritis and Cartilage, 2018, 26, 95-107.	1.3	23
23	Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice. PLoS ONE, 2018, 13, e0204911.	2.5	15
24	Inflammatory Cytokine Oncostatin M Induces Endothelial Activation in vitro and in APOE*3Leiden.CETP Mice. Atherosclerosis Supplements, 2018, 32, 19.	1.2	1
25	The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. Frontiers in Cardiovascular Medicine, 2018, 5, 55.	2.4	47
26	Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis, 2017, 257, 186-194.	0.8	17
27	The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. European Heart Journal, 2017, 38, 2499-2507.	2.2	176
28	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 211-221.	27.0	633
29	Cardiovascular safety of BCR-ABL1 tyrosine kinase inhibitors: imatinib and ponatinib decrease plasma cholesterol and atherosclerosis in APOE3*Leiden.CETP Mice. Atherosclerosis, 2017, 263, e29-e30.	0.8	0
30	Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. Atherosclerosis, 2017, 267, 116-126.	0.8	23
31	Affitope-based anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) vaccine (AT04A) reduces atherosclerosis in APOE*3Leiden.CETP mice. Atherosclerosis, 2016, 252, e253-e254.	0.8	0
32	The APOE*3Leiden.GK +/- mouse as novel translational model for dyslipidemia, type 2 diabetes and macrovascular complications. Atherosclerosis, 2016, 252, e226-e227.	0.8	1
33	Comment on â€œHypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of miceâ€•by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46â€“54. Toxicology Reports, 2016, 3, 306-309.	3.3	11
34	Salsalate attenuates diet induced nonâ€alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. British Journal of Pharmacology, 2015, 172, 5293-5305.	5.4	29
35	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials. European Journal of Pharmacology, 2015, 763, 48-63.	3.5	44
36	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. Pharmacological Research, 2015, 94, 1-8.	7.1	11

#	Article	IF	Citations
37	Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. European Heart Journal, 2015, 36, 39-50.	2.2	65
38	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. Journal of Lipid Research, 2015, 56, 2085-2093.	4.2	27
39	Metformin Lowers Plasma Triglycerides by Promoting VLDL-Triglyceride Clearance by Brown Adipose Tissue in Mice. Diabetes, 2014, 63, 880-891.	0.6	129
40	<scp>APOE</scp>*<scp>3Leiden</scp>.<scp>CETP</scp> transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes, Obesity and Metabolism, 2014, 16, 537-544.	4.4	42
41	PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. Journal of Lipid Research, 2014, 55, 2370-2379.	4.2	59
42	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. Journal of Lipid Research, 2014, 55, 2103-2112.	4.2	165
43	Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP miceâ€"a translational model for atherosclerosis. Annals of the Rheumatic Diseases, 2014, 73, 921-927.	0.9	67
44	Alirocumab, monoclonal antibody to PCSK9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in apoe*3leiden.cetp mice. Atherosclerosis, 2014, 235, e19.	0.8	1
45	Osteoarthritis development is induced by increased dietary cholesterol in APOE*3Leiden.CETP mice, a translational model for atherosclerosis, and can be inhibited by atorvastatin. Osteoarthritis and Cartilage, 2013, 21, S65-S66.	1.3	5
46	Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. Journal of Nutritional Biochemistry, 2013, 24, 1423-1430.	4.2	49
47	Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. Journal of Lipid Research, 2013, 54, 1255-1264.	4.2	15
48	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. PLoS ONE, 2013, 8, e63882.	2.5	14
49	Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. PLoS ONE, 2013, 8, e66467.	2.5	36
50	Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. Journal of Hypertension, 2012, 30, 107-116.	0.5	27
51	Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions. Toxicology Letters, 2012, 210, 360-365.	0.8	32
52	Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. Biochemical Pharmacology, 2012, 84, 821-829.	4.4	21
53	172 NIACIN, ATORVASTATIN AND FENOFIBRATE DECREASE PLASMA CETP BY REDUCTION OF THE HEPATIC MACROPHAGE CONTENT IN APOE*3-LEIDEN.CETP MICE. Atherosclerosis Supplements, 2011, 12, 38.	1.2	0
54	Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. British Journal of Pharmacology, 2011, 162, 1553-1563.	5.4	32

#	Article	IF	Citations
55	Perfluoroalkyl Sulfonates Cause Alkyl Chain Lengthâ€“Dependent Hepatic Steatosis and Hypolipidemia Mainly by Impairing Lipoprotein Production in APOE*3-Leiden CETP Mice. Toxicological Sciences, 2011, 123, 290-303.	3.1	118
56	CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice. Journal of Lipid Research, 2010, 51, 97-102.	4.2	7
57	Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice. Journal of Biological Chemistry, 2010, 285, 25168-25175.	3.4	28
58	P28 RESVERATROL PROTECTS AGAINST ATHEROSCLEROSIS DEVELOPMENT IN APOE*3-LEIDEN.CETP MICE. Atherosclerosis Supplements, 2010, 11, 22.	1.2	0
59	P70 THE EFFECT OF ALISKIREN ON ATHEROSCLEROSIS DEVELOPMENT IN APOE*3LEIDEN.CETP TRANSGENIC MICE WITH AND WITHOUT TREATMENT WITH ATORVASTATIN. Atherosclerosis Supplements, 2010, 11, 31.	1.2	0
60	P328 APOE*3LEIDEN.CETP TRANSGENIC MICE AS MODEL FOR THE METABOLIC SYNDROME. Atherosclerosis Supplements, 2010, 11, 86.	1.2	0
61	Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein. Endocrinology, 2009, 150, 2368-2375.	2.8	49
62	The dual PPARÎ±/Î³ agonist tesaglitazar blocks progression of preâ€existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. British Journal of Pharmacology, 2009, 156, 1067-1075.	5.4	34
63	PXR agonism decreases plasma HDL levels in ApoEâ€3-Leiden.CETP mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 191-197.	2.4	33
64	Preferential campesterol incorporation into various tissues in apolipoprotein E*3-Leiden mice consuming plant sterols or stanols. Metabolism: Clinical and Experimental, 2008, 57, 1241-1247.	3.4	13
65	Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein inAPOE*3Leiden.CETPMice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2016-2022.	2.4	161
66	The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. European Journal of Internal Medicine, 2008, 19, 115-121.	2.2	13
67	DUAL PPAR-ALPHA/GAMMA AGONIST TESAGLITAZAR BLOCKS PROGRESSION OF PRE-EXISTING ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP TRANSGENIC MICE. Atherosclerosis Supplements, 2008, 9, 209.	1.2	0
68	Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis, 2008, 197, 57-63.	0.8	76
69	Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation, 2008, 117, 2515-2522.	1.6	89
70	Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)*. Critical Care Medicine, 2008, 36, 2576-2582.	0.9	35
71	The Cholesterol-Raising Factor from Coffee Beans, Cafestol, as an Agonist Ligand for the Farnesoid and Pregnane X Receptors. Molecular Endocrinology, 2007, 21, 1603-1616.	3.7	107
72	Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. Journal of Lipid Research, 2007, 48, 1763-1771.	4.2	86

#	Article	IF	Citations
73	Mouse Models for Atherosclerosis and Pharmaceutical Modifiers. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1706-1721.	2.4	470
74	Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. Journal of Hypertension, 2007, 25, 2454-2462.	0.5	27
75	Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochemical and Biophysical Research Communications, 2007, 356, 674-680.	2.1	17
76	Anti-Atherosclerotic Effect of Amlodipine, Alone and in Combination With Atorvastatin, in APOE*3-Leiden/hCRP Transgenic Mice. Journal of Cardiovascular Pharmacology, 2006, 47, 89-95.	1.9	21
77	Cholesterol 7Î±-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2724-2730.	2.4	8
78	Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7Î±-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clinical Science, 2005, 108, 539-545.	4.3	32
79	Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E*3â€“Leiden Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 161-167.	2.4	77
80	Rosuvastatin Reduces Plasma Lipids by Inhibiting VLDL Production and Enhancing Hepatobiliary Lipid Excretion in ApoE*3-Leiden Mice. Journal of Cardiovascular Pharmacology, 2005, 45, 53-60.	1.9	21
81	CYP7A1 A-278C Polymorphism Affects the Response of Plasma Lipids after Dietary Cholesterol or Cafestol Interventions in Humans. Journal of Nutrition, 2004, 134, 2200-2204.	2.9	36
82	Well-Characterized Garlic-Derived Materials Are Not Hypolipidemic in APOE*3-Leiden Transgenic Mice. Journal of Nutrition, 2004, 134, 1500-1503.	2.9	6
83	Cholesterol 7Î±-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Impairs Very-Low-Density Lipoprotein Production. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 768-774.	2.4	24
84	Serum carotenoids and vitamins in relation to markers of endothelial. European Journal of Epidemiology, 2004, 19, 915-921.	5.7	112
85	Î±-Tocopherol levels in plasma in new-onset, insulin-dependent diabetes mellitus. European Journal of Internal Medicine, 2004, 15, 371-374.	2.2	4
86	Absence of an atheroprotective effect of the garlic powder printanor in APOE*3-Leiden transgenic mice. Atherosclerosis, 2004, 177, 291-297.	0.8	13
87	Evidence for anti-inflammatory activity of statins and PPARÎ± activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood, 2004, 103, 4188-4194.	1.4	166
88	Hepatic low-density lipoprotein receptorâ€“related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. Blood, 2004, 103, 3777-3782.	1.4	35
89	Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. Journal of Molecular and Cellular Cardiology, 2003, 35, 109-118.	1.9	26
90	Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 892-897.	2.4	56

#	Article	IF	Citations
91	Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterolâ€“Lowering Effect in APOE*3-Leiden Transgenic Mice. Circulation, 2003, 108, 1368-1374.	1.6	157
92	Differential Effects of Amlodipine and Atorvastatin Treatment and Their Combination on Atherosclerosis in ApoE*3-Leiden Transgenic Mice. Journal of Cardiovascular Pharmacology, 2003, 42, 63-70.	1.9	44
93	Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovascular Research, 2003, 57, 563-571.	3.8	49
94	Fibrates down-regulate IL-1â€“stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFÎºBâ€“C/EBP-Î² complex formation. Blood, 2003, 101, 545-551.	1.4	211
95	Genetic Analysis of Indicators of Cholesterol Synthesis and Absorption: Lathosterol and Phytosterols in Dutch Twins and Their Parents. Twin Research and Human Genetics, 2003, 6, 307-314.	1.0	17
96	Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis, 2002, 164, 65-71.	0.8	34
97	Design of a Targeted Peptide Nucleic Acid Prodrug To Inhibit Hepatic Human Microsomal Triglyceride Transfer Protein Expression in Hepatocytesâ€. Bioconjugate Chemistry, 2002, 13, 295-302.	3.6	33
98	Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a. Journal of Pediatrics, 2002, 140, 256-260.	1.8	40
99	HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice. Biochemical Pharmacology, 2002, 63, 1755-1761.	4.4	4
100	Dietary Plant Stanol Esters Reduce VLDL Cholesterol Secretion and Bile Saturation in Apolipoprotein E*3-Leiden Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1046-1052.	2.4	49
101	Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice. Circulation, 2001, 103, 1778-1786.	1.6	115
102	Cafestol Increases Serum Cholesterol Levels in Apolipoprotein E*3-Leiden Transgenic Mice by Suppression of Bile Acid Synthesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1551-1556.	2.4	42
103	Normal Oxidative Stress and Enhanced Lipoprotein Resistance to In Vitro Oxidation in Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2434-2440.	2.4	14
104	Acyl-coenzyme A: Cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7?-hydroxylase in cultured rat hepatocytes andin vivo in the rat. Hepatology, 1999, 30, 491-500.	7.3	47
105	LDL Oxidation and Extent of Coronary Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 193-199.	2.4	39
106	No Effect of Consumption of Green and Black Tea on Plasma Lipid and Antioxidant Levels and on LDL Oxidation in Smokers. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 833-841.	2.4	165
107	Cafestol, the Cholesterol-Raising Factor in Boiled Coffee, Suppresses Bile Acid Synthesis by Downregulation of Cholesterol 7Î±-Hydroxylase and Sterol 27-Hydroxylase in Rat Hepatocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3064-3070.	2.4	57
108	Structural Aspects of Bile Acids Involved in the Regulation of Cholesterol 7alpha-Hydroxylase and Sterol 27-Hydroxylase. FEBS Journal, 1995, 228, 596-604.	0.2	19

#	Article	IF	Citations
109	Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7Î±-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology, 1995, 21, 501-510.	7.3	88
110	Antioxidants and Coronary Heart Disease. Annals of Medicine, 1994, 26, 429-434.	3.8	56
111	Bile acids exert negative feedback control on bile acid synthesis in cultured pig hepatocytes by suppression of cholesterol 7Î±-hydroxylase activity. Hepatology, 1990, 12, 1209-1215.	7.3	23
112	Inhibition and induction of bile acid synthesis by ketoconazole effects on bile formation in the rat. Lipids, 1989, 24, 759-764.	1.7	12
113	Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins. Hepatology, 1986, 6, 1356-1360.	7.3	39
114	Free cytoplasmic messenger ribonucleoprotein complexes from rabbit reticulocytes. Molecular Biology Reports, 1979, 5, 59-64.	2.3	9